Israel Gasperin is a visionary entrepreneur, engineering scientist and the founder of Zentrela, a company dedicated to transforming cannabis research through advanced neurotechnology and AI. Under Israel’s leadership, Zentrela developed the Psychoactive Effect Level (PEL) metric, an innovative EEG-based measure capable of objectively assessing cannabis products' psychoactive potency. By combining wearable EEG technology with AI-driven EEG analysis, the PEL metric provides cannabis producers, researchers, and regulators with a non-invasive and cost-effective way to quantify product effects and maintain quality control. 



At CannMed 25, Israel will share results from over 10,000 EEG scans of consumers using a wide range of cannabis products in his oral presentation titled “Cannabis Effect Research Driven by EEG Technology and Machine Learning”.



During our conversation, we discuss: 




How Zentrela’s wearable EEG technology got its start measuring drowsiness in truck drivers  



The unreliability of consumer feedback with regards to cannabis product effects 



How the PEL metric was created to measure the unique psychoactive effects of cannabis



How producers can use PEL to objectively measure the quality and effectiveness of cannabis products beyond cannabinoid percentages 



Research findings that show THC% and PEL% are not directly correlated 



and more 




Thanks to This Episode’s Sponsor: The DENT Institute



With more than 300,000 patient visits per year, the DENT Neurologic Institute ranks among the largest neuroscience centers in North America. Its 24 subspecialty clinics often treat the most challenging neurologic conditions including but not limited to Migraine, Chronic pain, ALS, MS, Parkinson’s, Dementia, and Neuro-Oncology. With their mission of advancing neuroscience, the Dent Institute established a cannabis clinic in 2016 to aid in the treatment of these chronic conditions seen throughout the institute.



Learn more at dentinstitute.com



Additional Resources




Zentrela Website



Israel Gasperin on LinkedIn



Use of a Novel EEG-Based Objective Test, the Cognalyzer®, in Quantifying the Strength and Determining the Action Time of Cannabis Psychoactive Effects and Factors that May Influence Them Within an Observational Study Framework



Sensitivity, Specificity and Accuracy of a Novel EEG-Based Objective Test, the Cognalyzer®, in Detecting Cannabis Psychoactive Effects



Register for CannMed 25



Meet the CannMed 25 Speakers and Poster Presenters



Review the Podcast



CannMed Archive